Health
Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia – MD Linx
MDLinx original journal summary on Pneumonia, Infectious Disease from International Journal of Infectious Diseases
In the treatment of severe SARS-CoV-2 pneumonia (SSP), tocilizumab has been used with the aim to relieve the cytokine release syndrome (CRS)-induced acute respiratory distress syndrome (ARDS). Researchers here investigated the patients in whom it might benefit the most. Tocilizumab on a compassionate-use basis was provided to hospitalized patients with SSP (excluding intensive care and intubated cases) who required oxygen support to have a saturation > 93%. They studied a total of 207 patients and…
-
Noosa News23 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General18 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General23 hours agoOlder Aussies back increased superannuation tax
-
Noosa News21 hours agoTips to improve engagement – Proctor